Circumvention of chemoresistance in cancer may involve several modulator drugs with high affinity for the multidrug transporter P-glycoprotein (Pgp), which is expressed in a number of multi-resistant malignancies. Pgp acts as a membrane efflux pump with broad substrate specificity including antineoplastic drugs and endogenous substances such as certain cytokines and sphingolipids. Therefore, the consequence of Pgp blockade could be far more complex than intracellular drug retention. In the present study exposure of the Pgp inhibitor, PSC 833 (1200 ng/ml), to Pgp expressing KG1a/200 human leukemia cells provoked cell cycle arrest and apoptosis in vitro. This finding was put to test in vivo using a xenotransplant model of KG1a/200 human cells intravenously inoculated into non-obese diabetic severe combined immunodeficient (NOD-SCID) mice. The animals were randomly allocated to receive treatment with PSC 833 (n = 32) or placebo (n = 24). PSC 833 (30 mg/kg) was subcutaneously injected six or 12 times separated by 48-96 h. The overall mean whole blood concentration of PSC 833 was 1191 ± 60 ng/ml (s.e.m.) at 20 h after administration. Tumor engraftment was significantly reduced in the treatment group (P = 0.037), which also had prolonged survival compared to control animals (P = 0.0016). This is the first study that demonstrates antileukemic effects of a Pgp inhibitor as single agent therapy in vivo, and the present data raise the possibility of alternative exploitation of modulators in cancer chemotherapy.
Introduction
Failure to achieve complete and durable response limits the curative potential of antineoplastic agents in cancer treatment. Multidrug resistance (MDR) is thought to be a major cause of treatment failure. Frequently, MDR is associated with overexpression of the multidrug transporter, P-glycoprotein (Pgp), which is an integral plasma membrane protein capable of drug expulsion and maintenance of tolerable intracellular levels of certain cytotoxic drugs. 1, 2 Pgp has a broad specificity for multiple xenobiotics, 3 of which many are clinically important anticancer drugs with diverse structures and mechanisms of action. 4 High expression levels of Pgp in cancer cells have been shown to correlate negatively with chemosensitivity and survival in some solid tumors and various hematological malignancies. [5] [6] [7] [8] The interpretation of these data is not necessarily straightforward, because transport of growth regulating cytokines and phospholipids adds to the function of Pgp. [9] [10] [11] [12] This may indicate a potential role for Pgp in regulation of life and death processes in cancer cells.
The broad substrate specificity of Pgp also involves several non-cytotoxic drugs that competitively inhibit efflux of cytotoxic drugs by Pgp and thereby functionally downmodulate MDR. 13 Several modulators have been identified among drugs that were originally developed for other therapeutic indications, including calcium channel blockers, calmodulin antagonists, steroid hormonal agents and immunosuppressive agents.
14 These agents exercise a broad spectrum of pharmacological actions and side-effects, which limit their utility as MDR modulators. Therefore, a series of dedicated Pgp inhibitors with high affinity for Pgp and less toxic potential have been developed. The non-immunosuppressive cyclosporin PSC 833, 15 the acridonecarboxamide derivative GF120918, 16 the cyclopropyldibenzosuberane LY 335979, 17 and the anthranilic acid derivative XR9576 18 represent highly efficacious and potent Pgp modulators that are currently subject to widespread pre-clinical and clinical investigation.
PSC 833 is the most extensively studied among the new modulators, and has proven to be well tolerated in phase I and phase II clinical trials. [19] [20] [21] [22] Although the therapeutic value remains to be determined in larger populations, complete remissions have been achieved in heavily pre-treated, poorrisk patients with refractory cancer on the addition of PSC 833 to conventional chemotherapy. 20, 23 Whether this response hinges on drug sensitization only or could be attributable to other mechanisms as well is unclear. Due to the redundant physiological actions of Pgp the consequence of Pgp blockade is obviously far more complex than intracellular drug retention. Therefore, we studied in vitro and in vivo the single drug effect of PSC 833 on human leukemia cells with high expression levels of Pgp.
Comprehensive preclinical in vitro and in vivo studies have not shown any cytotoxic effect of PSC 833 per se (Investigator's Brochure on SDZ PSC 833, third edition, July 1996). However, previous studies in our laboratory have demonstrated that PSC 833 exercise a cytotoxic effect directed against multi-resistant leukemia cell lines characterized by overexpression of Pgp. 24 Our studies have also revealed that other Pgp inhibitors may exercise similar selective cytotoxicity. On the other hand, we could not find that non-Pgpmediated MDR was associated with susceptibility to the cytotoxic effects of these agents. In the present study, the cytotoxicity of PSC 833 in human multidrug-resistant KG1a/200 leukemia cells was characterized by flow cytometry, quantified by 3 H-thymidine DNA incorporation assay, and put to test in vivo using a xenotransplant model of these Pgp-expressing cells in NOD-SCID (non-obese diabetic severe combined immunodeficient) mice. Treatment with PSC 833 was compared with placebo in a randomized study. Tumor engraftment was significantly reduced in the treatment group, which was reflected in a prolonged survival compared to the control group.
Materials and methods

Cell line and in vitro analyses
The human myeloblastic MDR cell line KG1a/200 and the parental KG1a/0 cell line were maintained and propagated as previously described. 25 The RPMI 1640 growth medium (BioWhittaker, Walkersville, MA, USA) was supplemented with 10% fetal calf serum, L-glutamine (0.05 mM), streptomycin (100 g/ml), penicillin (100 U/ml), and nystatin (40 U/ml). Cell samples were washed with phosphate-buffered saline (PBS)/bovine serum albumin (BSA), stained with appropriate fluorochromes, and analyzed on FACScan (Becton Dickinson, San José, CA, USA) and Coulter Epics XL-MCL (Coulter Corporation, Miami, FL, USA) flow cytometers to generate fluorescence distributions. Pgp and CD34 immunofluorescence was obtained in viable cells for bi-variate analyses using a three-layer staining protocol with human specific primary antibodies. Green fluorescence (Pgp) was developed using a three-layer staining protocol. First, the cells were incubated for 60 min with 20 g/ml antihuman MRK16 antibody (Hoechst Japan, Kawagoe, Japan). The second and third incubation was performed with 100 l biotinylated horse antimouse IgG (1:35 dilution in PBS/BSA) and 100 l fluorescein isothiocyanate (FITC) streptavidin (1:35 dilution in PBS/BSA), respectively, for 30 min each. Red fluorescence (CD34) was generated by addition of 10 l phycoerythrin (PE)-conjugated antihuman CD34 antibody HPCA-2 (Becton Dickinson, San José, CA, USA) to the final layer.
Apoptotic cells were identified using flow cytometry and terminal deoxynucleotidyl transferase(TdT)-mediated d-uridine5Ј-triphosphate(dUTP)-biotin nick end-labeling (TUNEL) as described. 24 The TUNEL assay was combined with cell-kinetic analyses using propidium iodide (PI) to measure DNA content.
The in vitro cytotoxicity was quantified by measurements of 3 H-thymidine incorporation into the DNA of KG1a/0 and KG1a/200 cells subsequent to PSC 833 exposure at different concentrations (10-1500 ng/ml) for 96 h in Falcon 96-well tissue culture plates (Becton Dickinson Labware, Franklin Lakes, NJ, USA). Each well was supplemented with 10 l 3 Hthymidine (185 MBq/mmol) and incubated for an additional 18 h. An automatic harvester collected the cells on a glassfiber filter, and the radioactivity was measured using a liquid scintillation counter. Three replicate cultures were made for each dose level.
Study animals and in vivo conditions
The study population consisted of 56 female specific pathogen-free 6-to 8-week-old female NOD-SCID (scid/scid) mice (Bomholtgård Breeding and Research Center, Denmark). The study animals were caged in pairs or groups of three animals in Macrolon III cages in an individually ventilated cage system (B&K Universal, Nittedal, Norway) at constant temperature and humidity on a 12 h light and darkness schedule at an air exchange rate of 15 changes/h. The mice were fed a pelleted mouse diet (B&K Universal, Grimston, UK) and given tap water ad libitum. The animals were tested negative for parasitical, bacterial and viral agents according to the FEL-ASA recommendations. 26 Prior to the in vivo study the KG1a/200 cells were scaled up in multiple 25 cm 2 culture flasks by repeated passages. At day 0 of the study, 10 7 exponentially growing KG1a/200 cells Leukemia were injected into the tail vein of the study animals. Midazolam anesthesia was given if required during inoculation. Buprenorphin was administered if analgesia was required. Inspections were carried out daily throughout the observation period. The animal care was in accordance with national legislation and institutional guidelines.
Treatment
The animals were stratified by random in a study group (n = 32) and a control group (n = 24). The main portion of the study animals (n = 24) received 750 l PSC 833 injection solution 1 mg/ml (Novartis Pharma, Basel, Switzerland) subcutaneously on days 1, 3, 6, 9, 13 and 16. The remaining portion (n = 8) received additional treatment on days 20, 23, 27, 30, 34 and 37. The total exposure to PSC 833 was approximately 180 mg/kg and 360 mg/kg, respectively. The control animals were subjected to the same invasive procedures as they received 750 l placebo (vehicle) injection solution (Novartis Pharma) subcutaneously on days 1, 3, 6, 9, 13, and 16.
Surveillance and study end points
Primary end points were occurrence of malignancy and survival. Supplementary effect parameters were loss of weight and presence of blasts in peripheral blood. During surveillance the animals were closely monitored by daily inspection, bi-weekly weighing, and blood analyses every second week. Weight loss greater than 10% required daily weighing. Every fortnight, 150 l blood was collected and analyzed for lactate dehydrogenase (LD) by quantitative determination on the Roche/Hitachi 917 System automated clinical analyzer (Roche Diagnostics, IN, USA), LD isoenzymes using the Paragon LD Isoenzyme Electophorese Kit (Beckman Coulter, Fullerton, CA, USA), and morphological examination of blood smears. Criteria for extermination were weight loss у20%, incapacitating macroscopic tumors, or signs of severe illness defined as a combination of sluggish behavior, reduced activity, fur erection and curved disfiguration of the spine. The final decision to kill the animals was blinded with regard to the drug. The extermination was immediately followed by dissection of liver, spleen, femur, tibia, and any macroscopic tumors. Microscopic images were obtained from paraffin imbedded tissue blocks and stained with hematoxylin and eosin. The femora and tibiae were flushed with RPMI 1640 supplemented with 10% fetal calf serum to collect bone marrow for flow cytometric analyses. The study animals were observed for up to 92 days, and remaining healthy animals were killed at the end of the observation period.
Pharmacokinetics
The blood concentration of the cyclosporin PSC 833 was measured using Abbott TDx analyzer (Abbott Laboratories, Abbott Park, IL, USA) and cyclosporin A fluorescence-polarization immunoassay (FPIA) as previously described. 27 Because PSC 833 exhibits approximately 17% cross-reactivity with cyclosporin A, the FPIA offers a close correlation with standard HPLC assay of PSC 833. 28 Accordingly, the obtained values were multiplied by 5.7 to attain approximate PSC 833 blood concentrations.
Leukemia
Statistics
Prism software (GraphPad, San Diego, CA, USA) was used to perform comparisons of mean values by unpaired t-tests, for analyzing contingency tables by Fisher's exact test, and for analyzing survival by logrank test. Confidence intervals are given as ± standard error of the mean (s.e.m.). Histogram comparisons were carried out using CellQuest (Becton Dickinson, San José, CA, USA) for Kolmogorov-Smirnov statistics. P values Ͻ0.05 were regarded as statistically significant.
Results
The MDR cell line KG1a/200 was highly positive for Pgp. The expression level was six-fold higher than in the parental KG1a/0 cells (Figure 1a) . Interestingly, the two cell lines responded differently to PSC 833 exposure in vitro in terms of cell growth. By using 3 H-thymidine incorporation into the DNA as a measure of proliferation, we found that PSC 833 restrained growth of KG1a/200 cells selectively (Figure 1b) . The half-maximal growth inhibition dose (GI 50 ) was 276.1 ± 1.4 (s.e.m.) ng/ml, and very few cells (Ͻ4%) survived exposure to 1200 ng/ml of the modulator. In contrast, the parental KG1a/0 cells were unaffected by PSC 833 throughout the concentration range studied. Therefore, the following experiments were focused on the KG1a/200 cells. When they were exposed to a single dose of PSC 833 (1200 ng/ml), DNA fragments appeared within 48 h. Concurrently, proliferating G1 and S phase cells largely disappeared, the sub-G1 population increased, and hyper-diploid cells emerged in a combined TUNEL and DNA content flow cytometric assay ( Figure  2 ). The substantial destruction and redistribution of DNA are hallmarks of apoptosis and clearly demonstrate the cytotoxic potential of PSC 833.
To test the antineoplastic activity of PSC 833 in vivo, we used a model of xenotransplanted KG1a/200 cells in NOD-SCID mice. The cells were harvested in log phase and inoculated into the tail vein of 56 study animals. Subsequently, the animals received either PSC 833 (n = 32) or placebo (n = 24) as described, and the effects of PSC 833 on tumor engraftment and survival were studied for up to 92 days. The drug dosing was designed to obtain therapeutic blood concentrations of PSC 833. The overall mean whole blood concentration was 1191 ± 60 ng/ml (s.e.m.) when measured 20 h (C 20h ) after subcutaneous injections of 30 mg/kg PSC 833. Repeated injections did not result in drug accumulation as mean C 20h was 1228.9 ± 83.7 (s.e.m.) ng/ml after the first course, 1345.1 ± 67.9 (s.e.m.) ng/ml after the third course, and 1108.0 ± 130.5 (s.e.m.) ng/ml after the sixth course (Figure 3) . The drug and vehicle were apparently well tolerated, and no unfavorable effects could be registered in the treatment group or in the control group.
Overall, 15 animals (27%) developed macroscopic tumors. The tumors were unevenly distributed in the study population as 10 animals in the placebo group (42%) and five in the treatment group (16%) had histologically verified tumors. The underrepresentation of tumors in the treatment group was statistically significant (P = 0.037) by Fisher's exact test. Histologically, the tumors were myelosarcomas (chloromas) characterized by myeloid cells with large irregular nuclei (Figure 4 ) that had formed highly infiltrating tumors in bone and soft tissue (n = 6), thymus (n = 4), ovaries (n = 3), meninges (n = The bar-graph demonstrates mean through levels (C 20h ) of PSC 833 in NOD-SCID mice after injections 1, 3 and 6. The error bars represent the s.e.m. confidence intervals.
Figure 4
The microphotographs demonstrate dense myeloblastic infiltrate in striated muscle. The tumor cells have scanty eosinophilic cytoplasm and irregularly shaped nuclei, mainly without nucleoli. Scattered foci with apoptosis and mitosis can be seen. Hematoxylin and eosin staining, ×100 (a) and ×400 (b).
2), brain (n = 1), trachea (n = 1) and esophagus (n = 1). There were no differences in sites of macroscopic tumors between the groups. Interestingly, tumors did not develop in the eight animals receiving 12 treatment courses with PSC 833.
In bivariate flow cytometric analyses 99.8% of the KG1a/200 cells stained double positive for Pgp and CD34 using the human MDR1-specific MRK16 and the human CD34-specific anti-HPCA-2 monoclonal antibodies. Thus, the appearance of double positive Pgp
+ cells in marrow aspirates at autopsy was taken as evidence for marrow infiltration. Subpopulations of double-positive marrow cells were Leukemia found in 30 animals (54%) using a cut off level for +/+ relevant antibodies at the mean fraction + 2 s.e.m. of +/+ irrelevant antibodies. The marrow infiltration in the study animals was quite poor. The mean portion of Pgp
+ cells was as low as 3.8 ± 1.2% (s.e.m.), which is not comparable to the massive marrow infiltration commonly seen in humans with acute myeloblastic leukemia. The Pgp
+ phenotype appeared with equal frequency in the placebo group, 13/24 (54%), and in the treatment group, 17/32 (53%), at the time of death. Correspondingly, there was no correlation between the detection of Pgp
+ cells in bone marrow and the occurrence of tumors.
The enzyme lactate dehydrogenase (LD) is present in all human cells and catalyzes transformation of lactate to pyruvate. The serum levels of total LD and the corresponding isoenzymes LD1, LD2 or LD3 have been regarded as valid serological markers of tumor burden in human leukemia xenotransplanted SCID mice. 29 In the present study, electrophoretic separation of LD isoenzymes was performed to detect specific human isoenzymes in the murine blood samples as a measure of colonization and defoliation of human leukemia cells in the recipient. Human LD isoenzymes tended to appear more frequently among tumor-bearing mice 11/15 (73%) compared to the non-tumor-bearing mice 19/41 (46%), but the difference did not reach statistical significance. Furthermore, no difference in LD isoenzyme distribution could be found between the placebo and the treatment group. Thus, the LD isoenzymes appeared to be poor markers of tumor engraftment in the present study.
Development of incapacitating macroscopic tumors, weight loss у20% or general symptoms of distress were the criteria for extermination of animals during the study. By these measures we found that the crude survival of study animals was significantly prolonged compared with control animals using the logrank test (P = 0.0016) (Figure 5a) . To obtain tumor-free survival we censored the endpoints of distress and weight loss. Accordingly, the tumor-free survival was significantly improved in the study compared to the placebo group (P = 0.0018) (Figure 5b ). Treatment duration did not affect crude survival, but tumor-free survival was prolonged in animals that received 12 cycles of PSC 833 (P = 0.0407).
Discussion
The physiological function of Pgp includes transmembrane transport of a broad spectrum of endogenous substrates, some of which may play a role in cell growth regulation such as cytokines and sphingolipids. 30 During recent years several reports have suggested that Pgp may act as a primary antiapoptotic molecule protecting both non-neoplastic and neoplastic cells from various apoptotic stimuli. [31] [32] [33] [34] [35] [36] Furthermore, accumulating data from in vitro studies have shown that Pgpselective modulators separately inhibit cell growth and induce apoptosis in transformed T lymphocytes, leukemia, epidermoid carcinoma, and breast carcinoma cell lines. 24, [36] [37] [38] [39] [40] [41] In the present study, we have shown that the Pgp inhibitor PSC 833 exercise an anti-leukemic effect on xenotransplanted human leukemia cells in severely immundeficient mice. To our knowledge, this is the first time that such an effect of a Pgp modulator has been demonstrated in vivo.
Previously, we have hypothesized that interruption of the ability of Pgp to act as an efflux pump of endogenous substrates conferring survival signals may play a role in induction of apoptosis. Chaudhary and Roninson 42 have proposed that
Figure 5
The Kaplan-Meier plot demonstrates improvement of the crude survival in KG1a/200 human leukemia xenotransplanted NOD-SCID mice being treated with PSC 833 compared to placebo (P = 0.0016) (a). The tumor-free survival was also improved in the treatment group compared to the placebo group (P = 0.0018) (b). Censored subjects have been marked in the tumor-free survival plot.
Pgp in hematopoietic stem cells may participate in the export of a growth regulatory molecule. Interruption of a possible autocrine pathway supporting cell growth by endogenously produced and exogenously secreted cytokines may thus inhibit cell proliferation. Interleukin-2 (IL-2) is a growth regulatory molecule 43, 44 and a substrate of Pgp-mediated transport, 9, 10 but no study has so far shown that interruption of IL-2 transport by Pgp inhibition promotes apoptosis. On the other hand, List and colleagues 37 have demonstrated that inhibition by PSC 833 of the ABC1 transporter interrupts the efflux of IL-1␤ from cultured leukemia cells and causes apoptosis, which is avoided by exogenous substitution of IL-1␤. It is also known that both IL-3 and IL-6 may act as endogenous growth factors in autonomously growing leukemic cell lines, 45, 46 and endogenously produced GM-CSF may promote growth of malignant hematopoietic cells by secretion and binding to surface GM-CSF receptors. 47 Therefore, there are several candidates for a growth regulatory molecule working in an autocrine loop maintained by Pgp, but at present no study has provided proof of such a mechanism or identified the effector molecule.
An alternative explanation for the antiproliferative effect of PSC 833 has evolved from experiments that have disclosed increased intracellular content of ceramide in MDR cancer cells exposed to this agent. 39, 40 Ceramide is a potentially toxic sphingolipid which is involved in signaling events that result in G 0 /G 1 cell cycle arrest and apoptosis. 48, 49 The intracellular accumulation of ceramide is offset by ceramide glycosylation and removal of the glycosylation product, glucosylceramide, by Pgp. 11 Since glucosylceramide is not involved in execution of the cell death program, the net effect of ceramide glycosylation is antiapoptotic. The proapoptotic effect of PSC 833 is partly independent of Pgp blockade, because PSC 833 may augment ceramide formation and apoptosis in the Pgpdeficient cancer cells as well. 36, 50 However, no firm conclusions can yet be drawn with respect to the role of ceramide in apoptosis, because it is not entirely clear whether drugmediated generation of ceramide is essential for execution of the cell death program or simply represents a non-specific stress response.
The present study confirms that the KG1a/200 leukemia cells are sensitive to cytotoxic effects of PSC 833 in vitro. Previous experiments in our laboratory have indicated that the cytotoxicity is selective for leukemia cells with high expression levels of Pgp. 24 In these cells the half-maximal cytotoxic dose of PSC 833 is 250-300 ng/ml based on previous 38 and present observations using electronic cell counts and 3 H-thymidine incorporation, respectively, as measures of cytotoxicity. The in vitro studies were performed in cell culture media supplemented with 10% fetal calf serum. In 100% serum, which is closer to the clinical situation, the activity of PSC 833 is five-fold reduced because of protein binding. 51 Therefore, we set the target level for Pgp blockade at 1250 ng/ml. To reach this level in the study animals, we administered PSC 833 as 30 mg/kg subcutaneous injections, which was generally well tolerated, and yielded blood concentrations of about 1200 ng/ml 20 h after the injections. In man whole blood steady-state concentrations of 1200 ng/ml modulate Pgp function by increasing the retention of daunorubicin in Pgp + cells by approximately 40%. 21 This concentration has been well tolerated in man. Hence, the selected dose in this study gave adequate blood concentrations of PSC 388 in terms of antileukemic activity and tolerability. The dosing interval of 48-96 h did not result in drug accumulation. SCID mice have been widely used as recipients for xenotransplantation of human leukemia.
52-54 SCID mice carry defect B and T cell functions and normal macrophage and NK cell functions. 55 Tumor engraftment following xenotransplantation in SCID mice requires pre-treatment with irradiation (3.5-4 Gy) to reduce NK cell activity. 56 In SCID mice that have been transplanted with KG1 wild-type cells (closely related to KG1a), myeloblasts have been identified in peripheral blood 6-8 weeks after i.v. inoculation of 10 7 cells. 53 The NOD-SCID mice also carry a defect NK cell function, reduced compliment system and defect macrophage function. 57 We selected the NOD-SCID mice as recipients because they appear to have similar immune defects as irradiated SCID mice. However, the study animals did not develop leukemia in terms of massive marrow infiltration. Tumor engraftment occurred as granulocytic soft tissue sarcomas (chloromas), which are extramedullary tumors of myeloid origin. In man, chloromas frequently progress into acute myeloblastic leukemia within months if left untreated. 58 Therefore, an extension of the observation period in this study could possibly have led to the development of acute leukemia, but would have been unethical due to prolonged suffering of affected animals.
In this study we employed engraftment conditions without irradiation and growth factor supplements. Nevertheless, chloromas developed in 42% of the placebo animals inde-pendent of exogenous cytokines, thereby intimating that the KG1a/200 cells in the context of host stroma is capable of producing its own cytokines in an autocrine fashion. This possibility is in agreement with the idea that PSC 833 compromise the trafficking of potential growth factors mediated by Pgp, and could explain why only 16% of treated animals developed chloromas. However, the factors that potentially support growth of KG1a/200 human leukemia cells in NOD-SCID mice are so far unknown.
The present placebo-controlled study has demonstrated antileukemic effects of the Pgp modulator PSC 833 in vivo, and thus verified in vitro findings obtained in our laboratory and elsewhere. The antileukemic effect of PSC 833 in vitro involves both growth inhibition and execution of apoptotic cell death. Whether prevention of leukemia xenotransplant engraftment as shown in this study may translate into reduction of tumor burden in vivo should be addressed in further studies. The potential exploitation of PSC 833 as an antineoplastic agent is not in conflict with the use of PSC 833 as a sensitizing agent in combined regimens. On the contrary, the dual action could probably contribute to increase the potency of combination chemotherapy and introduce new options for selective drug treatment in cancer patients.
